Amphastar Pharmaceuticals (AMPH) Total Debt (2013 - 2026)

Amphastar Pharmaceuticals has reported Total Debt for 14 years, with the latest figure at $612.1 million in Q2 2026.

• On a quarterly basis, Total Debt rose 0.56% year-over-year to $612.1 million in Q2 2026; TTM through Jun 2026 was $612.1 million, a 0.56% increase from a year earlier, with the FY2025 full-year figure at $610.4 million, up 1.42% from the prior year.
• Total Debt was $612.1 million for Q2 2026 at Amphastar Pharmaceuticals, roughly flat from $611.5 million in the prior quarter.
• The five-year high for Total Debt was $638.6 million in Q3 2023, with the low at $75.0 million in Q1 2023.
• Average Total Debt over 5 years is $452.5 million, with a median of $595.6 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Total Debt jumped 743.74% in 2023, then decreased 6.57% in 2024.
• Over 5 years, Total Debt stood at $75.9 million in 2022, then surged by 677.51% to $590.0 million in 2023, then gained by 2.01% to $601.9 million in 2024, then climbed by 1.42% to $610.4 million in 2025, then gained by 0.27% to $612.1 million in 2026.
• The last three Total Debt figures came in at $612.1 million (Q2 2026), $611.5 million (Q1 2026), and $610.4 million (Q4 2025), per Business Quant data.